Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 손영동, 주식회사 종근당filedCritical손영동
Priority to KR1019920009865ApriorityCriticalpatent/KR930000119A/en
Publication of KR930000119ApublicationCriticalpatent/KR930000119A/en
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
제1도는 본 발명에 따르는 캡슐 코팅 제제에서 얻어지는 혈중 오메프라졸 농도를 시판하고 있는 한국 공개 특허 제87-4132호에 의한 제품에서 얻어지는 혈중 농도와 비교하여 도시한 그래프이다.FIG. 1 is a graph showing the blood omeprazole concentration obtained in the capsule coating formulation according to the present invention in comparison with the blood concentration obtained in the product according to Korean Patent Application No. 87-4132.
Claims (2)
오메프라졸 및 오메프라졸염과 부형제를 충전시킨 경질 제라틴 캡슐에 결합제로 캡슐의 이음새 부분을 밴딩하고, 그위에 장용성 코팅을 하는 것을 특징으로 하는 유효성분을 오메프라졸을 함유하는 경구용약제.An oral pharmaceutical solution containing omeprazole as an active ingredient characterized in that the hard gelatine capsules filled with omeprazole and omeprazole salts and excipients are banded together with a binder and an enteric coating thereon.제1항에 있어서, 부형제가 염기성 아미노산 중에서 선택되는 것인 경구용 약제.The oral drug of claim 1, wherein the excipient is selected from basic amino acids.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920009865A1992-06-081992-06-08
New Oral Medicines
KR930000119A
(en)